why choose us

First received: December 11, 2022

Clinical Trial: Glycation of apoA-I and Diabetic Atherogenesis

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Diabetes Mellitus, Type 2

Study Type: Observational


Official Title: The Impact of Glycation Modification of apoA-I on HDL Function and Atherogenesis in Type Diabetes Mellitus

Brief Summary: The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site…

Read more